Calidi Biotherapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Material Modifications to Rights of Security Holders

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Submission of Matters to a Vote of Security Holders

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

No description available

Prospectus Supplement with Pricing Information

Notice of Effectiveness

Registration (IPO) statement under Securities Act of 1933

Notice of Effectiveness

Registration statement under Securities Act of 1933

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Sanders Corazon (Corsee) D.

Peoples George

Stewart Alan R.

Leftwich Scott

Jackson Andrew C.

Schoeneck James A

Poma Eric E

Fernandez Santidrian Antonio

ARMISTICE CAPITAL, LLC

Sanders Corazon (Corsee) D.

ARMISTICE CAPITAL, LLC

Gavrilov Ognian Anguelov

Gavrilov Ognian Anguelov

Lincoln Alternative Strategies LLC

Gavrilov Ognian Anguelov

Camaisa Allan

Poma Eric E

Fernandez Santidrian Antonio

Jackson Andrew C.

Lincoln Alternative Strategies LLC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Draft registration statement (confidential submission)

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC